EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Can axillary lymph node dissection be omitted in breast cancer patients with 1-2 positive sentinel nodes? A systematic review and meta-analysis

Jinyi Xie, Tong Wan, Jie Hao, Siyue Zhang, Haoyu Wang, Xiaochen Zhang, Pengfei Zhu, Lijuan Wang, Bing Chen, Wenjing Zhao, Qifeng Yang iD, Ning Zhang iD

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf379 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Oncologist, 2025. Verfasst von Jinyi Xie und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Qilu Hospital of Shandong University, Jinan 250012, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Lymph Node Excision, Sentinel Lymph Node. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Mount Taishan Scholar Young Expert, Natural Science Foundation of Shandong Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Axillary lymph node dissection (ALND) has traditionally been recommended for breast cancer patients with positive sentinel lymph nodes (SLNs). Although omitting ALND is now widely accepted for patients undergoing breast-conserving surgery (BCS) with limited sentinel lymph node biopsy (SLNB) involvement, based on trials such as Z0011, evidence for patients undergoing total mastectomy (TM) remains limited and conflicting. This meta-analysis aimed to evaluate whether ALND can be safely omitted in TM patients with 1-2 positive SLNs by comparing survival outcomes between ALND and SLNB alone groups.

Methods

A systematic search of PubMed, Embase, Cochrane Library, and Web of Science (up to December 2024) identified 29 studies (6 randomized controlled trials and 23 observational) involving a total of 146 407 patients. Survival outcomes, including overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS), were pooled using random- or fixed-effects models. Heterogeneity and publication bias were assessed using I2 statistic, Begg’s test, and Egger’s test. Subgroup analyses were performed based on study design, type of surgical (TM vs. BCS), and pathological T-stage.

Results

Overall, no significant differences in OS (OR = 0.93, 95% confidence interval [CI]: 0.83-1.04), DFS (OR = 1.02, 95% CI: 0.87-1.20), or RFS (OR = 1.08, 95% CI: 0.89-1.30) were observed between ALND and SLNB alone groups. However, in the TM subgroup, ALND was associate with improved OS (OR = 0.75, 95% CI: 0.62-0.90). Similarly, patients with T3-4 tumors demonstrate better OS outcomes with ALND. No significant differences in DFS or RFS were observed across subgroups.

Conclusion

SLNB alone provides comparable survival outcomes to ALND in early breast cancer (EBC) patients with 1-2 positive SLNs, supporting its safety in those undergoing BCS. However, while our analysis suggests a potential survival advantage with ALND in TM patients and those with advanced T-stage (T3-4), this observation requires cautious interpretation due to potential selection bias, residual confounding from unmeasured variables and confounding by indication where ALND may reflect more intensive multimodal therapy rather than causally improving OS. Therefore, these subgroup findings should not be considered practice-changing at this stage. Further high-quality prospective studies are warranted to validate these associations and optimize patient selection criteria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsLymph Node ExcisionSentinel Lymph NodeHumansFemaleAxillaSentinel Lymph Node BiopsyLymphatic MetastasisMastectomy

Stichwörter der Autor:innen

axillary lymph node dissectionbreast cancerbreast-conserving surgerysentinel lymph node biopsysurvival outcometotal mastectomy

Autor:innen und Institutionen

  • Department of Breast Surgery, Qilu Hospital of Shandong University, Jinan 250012, China.
  • Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan 250012, China.
  • Biological Resource Center, Qilu Hospital of Shandong University, Jinan 250012, China.
  • Research Institute of Breast Cancer, Shandong University, Jinan 250012, China.

ORCID-Profile: Qifeng Yang, Ning Zhang

Förderung

  • Mount Taishan Scholar Young Expert
  • Natural Science Foundation of Shandong Province
  • National Natural Science Foundation of China

Zitieren

APA

Xie, J., Wan, T., Hao, J., Zhang, S., Wang, H., Zhang, X., Zhu, P., Wang, L., Chen, B., Zhao, W., Yang, Q., & Zhang, N. (2025). Can axillary lymph node dissection be omitted in breast cancer patients with 1-2 positive sentinel nodes? A systematic review and meta-analysis. The Oncologist. https://doi.org/10.1093/oncolo/oyaf379

Vancouver

Xie J, Wan T, Hao J, Zhang S, Wang H, Zhang X, et al. Can axillary lymph node dissection be omitted in breast cancer patients with 1-2 positive sentinel nodes? A systematic review and meta-analysis. The Oncologist. 2025. doi:10.1093/oncolo/oyaf379

BibTeX
@article{Xie2025,
  author = {Xie, Jinyi and Wan, Tong and Hao, Jie and Zhang, Siyue and Wang, Haoyu and Zhang, Xiaochen and Zhu, Pengfei and Wang, Lijuan and Chen, Bing and Zhao, Wenjing and Yang, Qifeng and Zhang, Ning},
  title = {Can axillary lymph node dissection be omitted in breast cancer patients with 1-2 positive sentinel nodes? A systematic review and meta-analysis},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf379}
}
Kostenlos starten →